Insider and Institutional Ownership
17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 7.9% of Graybug Vision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Avenue Therapeutics has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Profitability
This table compares Avenue Therapeutics and Graybug Vision’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
| Graybug Vision | N/A | -77.61% | -71.34% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | ($0.94) | -0.70 |
| Graybug Vision | $426.96 million | 0.00 | -$35.60 million | ($24.23) | -0.02 |
Avenue Therapeutics has higher earnings, but lower revenue than Graybug Vision. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Summary
Graybug Vision beats Avenue Therapeutics on 5 of the 9 factors compared between the two stocks.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
About Graybug Vision
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
